What is your scientific background?
My scientific background is shaped by a combination of a Bachelor’s in Biotechnology with a Master’s in Stem Cell Sciences, providing me with a strong foundation in molecular biology and human physiology, with a specialisation in developmental biology. During my Master’s, it was stem cells that fascinated me the most – the embryonic cells; and the gametes that give rise to it, the egg and sperm. This curiosity led me to pursue a PhD in the Laboratory of Reproductive Biology at Rigshospitalet, where I focused on advancing clinical tools to improve female fertility preservation in cancer patients. Currently, with funding from ReproUnion, I am continuing my PhD research while expanding into projects exploring ovarian and follicular physiology, as well as the molecular pathways involved in follicular atresia at different stages of folliculogenesis.
You are involved in one of ReproUnion’s seven innovation projects. Can you briefly describe your role?
Yes, our project aims to investigate the regulatory mechanisms of follicular atresia, the process by which most ovarian follicles degenerate before ovulation. Understanding these mechanisms is crucial for preserving the follicular reserve and optimising fertility treatments. In collaboration with Professor Johan Malm from Lund University, we have analysed the protein composition of follicular fluid (FF), which reflects the microenvironment of developing oocytes. By comparing FF from healthy and atretic follicles, matched by patient and follicular stage, the research seeks to identify key molecular pathways driving follicular atresia. These insights could help delay ovarian exhaustion and improve follicle recruitment in IVF cycles.
What made you enter the field of reproductive health?
As I mentioned earlier, I have always been fascinated by the biology of embryos and gametes. It is incredible to think that a single-cell embryo has the potential to develop into a complete human being and even form the placenta. The female gamete, the egg, is particularly remarkable, it is the largest cell in the human body, as it must be loaded with regulatory molecules to support the earliest stages of embryo development. Additionally, women are born with a finite number of eggs that must last throughout their entire reproductive lifespan, making their biology even more intriguing.
Beyond the science, I believe reproductive health research has a societal impact. With fertility rates declining in most developed countries, advancing our understanding of reproductive biology is more important than ever. This research not only helps address urgent questions in fertility but also lays the foundation for future breakthroughs that could be crucial for generations to come.
You are also involved in ReproYoung that re-launched this year. Can you say a few words about being part of this network?
Yes, we re-started ReproYoung in 2024, to continue many of the good initiatives from the original network. Our goal is to create a dynamic platform for early career scientists working in reproductive science, a space where we can network, collaborate, and drive forward different initiatives. One of our key projects is organising ReproTalks, a series of evening symposiums, and we are also working to secure funding for a two-day conference. Being part of ReproYoung is an incredible experience. It is inspiring to work alongside passionate researchers who share similar interests, ideals, and goals for shaping the future of reproductive science. The energy and enthusiasm within the network make it a great community to be a part of.